tics in general, and the TOMM40 biomarker specifically, to identify at-risk individuals who may be candidates for treatment in a pharmacogenetics-assisted clinical trial," said Dr. Roses. "We look forward to working with a partner like Takeda, who shares our commitment to reducing the prevalence of Alzheimer's disease over the next 20-30 years."
Alzheimer's disease is a degenerative brain disease characterized by a progressive decline in memory, thinking, comprehension, calculation, language, learning capacity and judgment sufficient to impair personal activities of daily living. Approximately 18 million people worldwide are currently suffering from Alzheimer's disease, and the rate of occurrence doubles every five years for those between 65 and 85 years of age.
About Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.
About Zinfandel Pharmaceuticals
Zinfandel Pharmaceuticals, based in Durham, NC, is a privately held company dedicated to using pharmacogenetics to improve prediction of risk for Alzheimer's disease and thus facilitate the development of effective therapies.
Page: 1 2 Related biology technology :1
|SOURCE Takeda Pharmaceutical Company Limited; Zinfandel Pharmaceutcals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research2
. FDA Continues Review of Takedas New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes3
. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT4
. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results5
. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 20086
. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results7
. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist8
. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference9
. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman10
. Access Pharmaceuticals to Present at the Noble Financial Equity Conference11
. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)